Last reviewed · How we verify

Loteprednol etabonate 0.5% and tobramycin 0.3%

Bausch & Lomb Incorporated · FDA-approved active Small molecule Quality 5/100

Loteprednol etabonate 0.5% and tobramycin 0.3% is a Small molecule drug developed by Bausch & Lomb Incorporated. It is currently FDA-approved. Also known as: Zylet.

At a glance

Generic nameLoteprednol etabonate 0.5% and tobramycin 0.3%
Also known asZylet
SponsorBausch & Lomb Incorporated
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Loteprednol etabonate 0.5% and tobramycin 0.3%

What is Loteprednol etabonate 0.5% and tobramycin 0.3%?

Loteprednol etabonate 0.5% and tobramycin 0.3% is a Small molecule drug developed by Bausch & Lomb Incorporated.

Who makes Loteprednol etabonate 0.5% and tobramycin 0.3%?

Loteprednol etabonate 0.5% and tobramycin 0.3% is developed and marketed by Bausch & Lomb Incorporated (see full Bausch & Lomb Incorporated pipeline at /company/bausch-lomb-incorporated).

Is Loteprednol etabonate 0.5% and tobramycin 0.3% also known as anything else?

Loteprednol etabonate 0.5% and tobramycin 0.3% is also known as Zylet.

What development phase is Loteprednol etabonate 0.5% and tobramycin 0.3% in?

Loteprednol etabonate 0.5% and tobramycin 0.3% is FDA-approved (marketed).

Related